newsfilter
← Latest News
Business Wire·

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic control arm data being developed at the request of FDA to support a Breakthrough Therapy Designation request, to be presented at MIB Factor in